PanTracer Tissue + HRD

PanTracer Tissue + HRD offers CGP with integrated HRD assessment. Our advanced HRD score assesses BRCA1/2 and tumor genomic instability (GIS), including loss of heterozygosity (LOH), telomeric allelic imbalance (TAI), and large-scale state transitions (LST), to guide personalized treatment decisions.

With real-time molecular insights, PanTracer Tissue + HRD supports more informed, precise, and effective treatment strategies across the ovarian cancer care continuum.

COMING SOON